LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--BioSante Pharmaceuticals, Inc. (Amex: BPA) today announced that it has signed an exclusive agreement with Pantarhei Bioscience, a Netherlands-based pharmaceutical company for the development and marketing of an oral contraceptive in the United States. BioSante will co-fund the early development of the oral contraceptive up to $1.0 million. Pantarhei will be responsible for all other expenses to develop and market the product.
